MOLECULAR MARKERS AS A DIAGNOSTIC TOOL AND PROGNOSTIC FACTOR IN BONE TUMOR PATHOLOGY

DOI: https://doi.org/None

I.V. Boulytcheva Polyclinic № 1 of the Business Administration for the President of the Russian Federation, Sivtsev Vrazhek side street, Bld 26/28, Moscow, Russian Federation, 119002

Among oncology diseases the primary bone tumors make up to 0,7–2,0% of all malignancies. The peak of morbidity caused by bone tumors falls on the age of person’s social activity. Bone tumors are one of the most aggressive among malignant human tumors. That’s why one of the most adequate treatments is the combined method consisting of inductive (systematic, regional) multiagent chemotherapy together with tumor local control method (operative intervention, radiation therapy). Modern possibilities of oncoortopedics can really improve both the quality of life and treatment outcomes for these patients. The group of primary bone tumors is a rare and diverse group of human neoplasms. Among the malignant tumors, they account for less than 1% among adults and up to 10% among children. Great progress in the treatment of these diseases has been achieved during the last two decades. Thanks to the modern chemotherapy and to the improvement in imaging technologies of bone cancer tumors together with the successes of orthopedics the majority of patients can be cured at the present time and the limb can be saved more than in 80% of cases.
Keywords: 
bone sarcoma, immunohistochemistry, molecular markers
Список литературы: 
  1. Gokgoz N., Wunder J.S., Mousses S. et al. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer. 2001; 92 (8): 2181–9.
  2. Ferrara N., Gerber H.-P., LeCouter J. The biology of VEGF and its 448 receptors. Nat. Med. 2003; 9 (6): 669–76.
  3. Nedelcu T., Kubista., Koller A. et al. Livin and Bcl-2 expression in high-grade osteosarcoma. J. Cancer Res. Clin. Oncol. 2008; 134 (2): 237–44.
  4. Chan S.L., Yu V.C. Proteins of the Bcl-2 family in apoptosis signaling: from mechanistic insights to therapeutic opportunities. Clin. Exp. Pharmacol. Physiol. 2004; 31 (3): 119–28.
  5. Lambert P.F., Sugden B. Viruses in cancer. In: Abeloff M., Armitage J., Niederhuber J., Kastan M., McKenna W., eds. Clinical oncology, 3rd ed. New York: Elsevier. 2004; 207–25.
  6. DuBois S., Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer. 2007; 109 (5): 813–9.
  7. Kansara M., Thomas D.M. Molecular pathogenesis of osteosarcoma. DNA Cell. Biol. 2007; 26 (1): 1–18.
  8. Posl M., Amling M., Werner M. et al. Osteosarcoma – apoptosis and proliferation. Study of Bcl-2 expression. Pathologe. 1994. 15 (6): 337–44.
  9. Rozeman L.B., Hameetman L., Cleton-Jansen A.-M. et al. Absence of IHH and retention of PTHrP signaling in enchonromas and central chondrosarcomas. J. Pathol. 2005; 205 (4): 476–82.
  10. Link M.P., Gebhardt M.C., Meyers P.A. Osteosarcoma. In: Pizzo P.A., Poplack D.G., editors. Principles and practice
  11. of pediatric oncology. Philadelphia:
  12. Lippincott Williams & Wilkins; 2006; 1074–115.
  13. Urakawa H., Nishida Y., Naruse T. et al. Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study. Clin. Orthop. Relat. Res. 2009; 467 (11): 2932–8.
  14. Mullins M.N., Lana S.E., Dernell W.S. et al. Cyclooxygenase-2 expression in canine appendicular asteosarcomas. J. Vet. Intern. Med. 2004; 18 (6): 859–65.
  15. Xu Z., Choudhary S., Voznesensky O. et al. Overexpression of Cox-2 human osteosarcoma cells decreases proliferation and increased apoptosis. Sancer Res. 2006; 66 (13): 6657–64.
  16. 14. Minoo P, Baker K, Baumhoer D, et al. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. Hum.Pathol. 2010; 41: 70–8.
  17. Ferrari S., Bertoni F., Zanella L. et al.
  18. Evaluation of P-glycoprotein,
  19. HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade
  20. osteosarcoma. Cancer. 2004; 100 (9): 1936–42.
  21. Weinberg R.A. The biology of cancer NY, Oxford: Garland Science, 2007.
  22. Rodrigues N.I., Hoots W.K., Koshkina N.V. et al. COX-2 expression correlates with survival in patients with osteosarcoma lung metastases. J. Pediatr. Hematol. Oncol. 2008; 30 (7): 507–12.
  23. Kubo T., Shimose S., Matsuo T. et al. Interferon α/β receptor as a prognostic factor in osteosarcoma. J. Joint Bone Surg. Am. 2011; 93 (6): 519–26.